OHRP Stock News 6.87 05/09/2014 19:24:18 Ohr Pharmaceutical Inc
Post# of 273250
Posted On: 05/09/2014 8:24:20 PM
Ohr Pharmaceutical Inc (OHRP) 6.87 $OHRP
Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
GlobeNewswire - Fri May 09, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME).
Regeneron-Avalanche Partnership Underscores Ohr Pharma's Eye-Disease Isolation
at The Street - Mon May 05, 8:54AM CDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously.
Vista Partners Publishes May 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri May 02, 8:01AM CDT
Vista Partners ("Vista"
published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Adtech, Biotechnology, Travel, Energy, Healthcare, Kentucky Derby, Gold, Natural Resources & More.
5 Stocks Under $10 Set to Soar
at The Street - Thu May 01, 1:30PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Ohr Pharmaceutical concludes patient enrollment in the US in Phase II clinical trial of Squalamine Eye Drops in Wet-AMD
M2 - Wed Apr 30, 3:52AM CDT
Pharmaceutical company Ohr Pharmaceutical (NasdaqCM:OHRP) disclosed on Tuesday the completion of patient enrollment as part of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration (wet-AMD).
Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
GlobeNewswire - Tue Apr 29, 4:00AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD" . The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year. Final data are expected in the first calendar quarter of 2015.
3 Stocks Rising on Big Volume
at The Street - Thu Apr 10, 8:26AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has entered into subscription agreements with institutional and accredited investors for the sale of its common stock in a registered direct offering. The Company is selling 1.8 million shares of common stock at a price of $10.00 per share, for gross proceeds of approximately $18 million. Chardan Capital Markets, LLC acted as lead placement agent and Brean Capital, LLC acted as co-placement agent for the offering. The sale and issuance of the shares is expected to close on or about April 11, 2014.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Fight! DJIA and S&P vs. Nasdaq and Russell 2000
at The Street - Tue Mar 25, 3:44PM CDT
Tuesday was another wild ride in the markets. Nothing seems to be able to keep the DJIA and S&P down. The Nasdaq and Russell 2000 are another story.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Strength Seen in Ohr Pharmaceutical, Inc. (OHRP) Stock Shoots 22% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:44AM CDT
Ohr Pharmaceutical, Inc. was a big mover last session, as the company saw its shares surge 22% on the day.
Ohr Pharmaceutical to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Irach Taraporewala, Ph.D., Chief Executive Officer and President, will present a corporate overview and business update at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Ohr Pharmaceutical and Cold Spring Harbor Laboratory Announce Joint Venture to Develop Trodusquemine and Related Analogs
GlobeNewswire - Mon Mar 03, 4:00AM CST
Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Positive Case Report on Ohr Pharmaceutical's Squalamine Presented at the 37th Annual Macula Society Meeting
Marketwire - Thu Feb 20, 7:59AM CST
Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that a case report on the first patient treated in an ongoing investigator sponsored trial ("IST" with Squalamine eye drops in proliferative diabetic retinopathy ("PDR" was presented yesterday at the 37th Annual Macula Society Meeting, in Key Largo, Florida. Diabetic retinopathy is the second most common cause of vision loss. In PDR, abnormal blood vessels (neovascularization) grow from the retina into the vitreous cavity of the eye, resulting in blindness if untreated. The case report was presented by the lead investigator, Michael J. Elman, M.D., Director of the Elman Retina Group from Baltimore, Maryland.
Ohr Pharmaceutical (OHRP) Catches Eye: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 10%.
Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
GlobeNewswire - Fri May 09, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II investigator sponsored clinical trial, OHR-005, testing Squalamine Eye Drops in patients with diabetic macular edema (DME).
Regeneron-Avalanche Partnership Underscores Ohr Pharma's Eye-Disease Isolation
at The Street - Mon May 05, 8:54AM CDT
The Regeneron-Avalanche partnership and the hedge funds investment in the latter is more indirect evidence that Ohr Pharmaceuticals and its AMD eye drop Squalamine are not taken seriously.
Vista Partners Publishes May 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri May 02, 8:01AM CDT
Vista Partners ("Vista"
published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Adtech, Biotechnology, Travel, Energy, Healthcare, Kentucky Derby, Gold, Natural Resources & More. 5 Stocks Under $10 Set to Soar
at The Street - Thu May 01, 1:30PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Ohr Pharmaceutical concludes patient enrollment in the US in Phase II clinical trial of Squalamine Eye Drops in Wet-AMD
M2 - Wed Apr 30, 3:52AM CDT
Pharmaceutical company Ohr Pharmaceutical (NasdaqCM:OHRP) disclosed on Tuesday the completion of patient enrollment as part of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration (wet-AMD).
Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
GlobeNewswire - Tue Apr 29, 4:00AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD"
. The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year. Final data are expected in the first calendar quarter of 2015. 3 Stocks Rising on Big Volume
at The Street - Thu Apr 10, 8:26AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has entered into subscription agreements with institutional and accredited investors for the sale of its common stock in a registered direct offering. The Company is selling 1.8 million shares of common stock at a price of $10.00 per share, for gross proceeds of approximately $18 million. Chardan Capital Markets, LLC acted as lead placement agent and Brean Capital, LLC acted as co-placement agent for the offering. The sale and issuance of the shares is expected to close on or about April 11, 2014.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Fight! DJIA and S&P vs. Nasdaq and Russell 2000
at The Street - Tue Mar 25, 3:44PM CDT
Tuesday was another wild ride in the markets. Nothing seems to be able to keep the DJIA and S&P down. The Nasdaq and Russell 2000 are another story.
Can Ohr Pharmaceutical (OHRP) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:52AM CDT
Ohr Pharmaceutical has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Strength Seen in Ohr Pharmaceutical, Inc. (OHRP) Stock Shoots 22% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:44AM CDT
Ohr Pharmaceutical, Inc. was a big mover last session, as the company saw its shares surge 22% on the day.
Ohr Pharmaceutical to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Irach Taraporewala, Ph.D., Chief Executive Officer and President, will present a corporate overview and business update at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Ohr Pharmaceutical and Cold Spring Harbor Laboratory Announce Joint Venture to Develop Trodusquemine and Related Analogs
GlobeNewswire - Mon Mar 03, 4:00AM CST
Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Positive Case Report on Ohr Pharmaceutical's Squalamine Presented at the 37th Annual Macula Society Meeting
Marketwire - Thu Feb 20, 7:59AM CST
Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that a case report on the first patient treated in an ongoing investigator sponsored trial ("IST"
with Squalamine eye drops in proliferative diabetic retinopathy ("PDR" was presented yesterday at the 37th Annual Macula Society Meeting, in Key Largo, Florida. Diabetic retinopathy is the second most common cause of vision loss. In PDR, abnormal blood vessels (neovascularization) grow from the retina into the vitreous cavity of the eye, resulting in blindness if untreated. The case report was presented by the lead investigator, Michael J. Elman, M.D., Director of the Elman Retina Group from Baltimore, Maryland. Ohr Pharmaceutical (OHRP) Catches Eye: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 10%.
(0)
(0)Scroll down for more posts ▼